MultiplexDX International

MultiplexDX Inc. is an international corporation established in 2015 with units in both Maryland, US, and Slovakia. The company's slogan is "Eliminating cancer misdiagnosis by launching a new diagnostic test in 2023 and operating a boutique oligo house." MultiplexDX aims to achieve this by introducing a 98% accurate, quantitative, and accessible diagnostic test to eliminate cancer misdiagnosis. Additionally, the company operates a boutique oligohouse offering highly specialized custom oligonucleotides to the research community. The mission of MultiplexDX is to transform breast cancer treatment non-responders into responders, ensuring durable responses and aiming to drastically increase survival rates by at least 50%. This ambitious mission is supported by several objectives, including the development of technologies and products for molecular diagnostic markets superior to currently available products, core facility services using proprietary Multiplex TM technology, and the development of hi-tech 3D digital pathology services. The company's last investment was a grant investment received on 24 September 2019 from IPA4SME. MultiplexDX operates in the biotechnology and pharmaceutical industries and is headquartered in the United States. For more information about MultiplexDX, you can visit their official website and follow them on social media: - Website: www.multiplexdx.com - Facebook: MultiplexDX on Facebook - Twitter: MultiplexDX on Twitter - Google Plus: MultiplexDX on Google Plus - YouTube: MultiplexDX on YouTube